RxDoctor Payments Data

Yelena Korenfeld, MD

Internal Medicine · Cliffside Park, NJNPI 1720094576

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 41 payments — averaging $47.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$365
  • AbbVie$341
  • Lilly USA, LLC$125
  • Amgen$70
  • Kowa Pharmaceuticals America, Inc.$28
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$1,94399%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,959 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$384,013
Medicare patients
180
Services billed
3,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$17,038
EliquisApixaban21$15,872
VascepaIcosapent Ethyl48$14,869
TrintellixVortioxetine Hydrobromide24$11,330
JanuviaSitagliptin Phosphate16$8,974
Dexlansoprazole DrDexlansoprazole25$8,007
Diclofenac Sodium37$3,904
Icosapent Ethyl25$3,887
Esomeprazole Magnesium29$3,222
Advair DiskusFluticasone Propion/Salmeterol16$3,160
Clonidine18$1,794
Rosuvastatin Calcium144$1,418
SynthroidLevothyroxine Sodium17$1,131
Ibandronate Sodium69$1,054
Valsartan13$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$365$17,03817 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$13$11,33024 claims
AbbVieSynthroid$341$1,13117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Cliffside Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →